CN112931883A - Prebiotic composition and preparation method and application thereof - Google Patents
Prebiotic composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN112931883A CN112931883A CN202110313079.3A CN202110313079A CN112931883A CN 112931883 A CN112931883 A CN 112931883A CN 202110313079 A CN202110313079 A CN 202110313079A CN 112931883 A CN112931883 A CN 112931883A
- Authority
- CN
- China
- Prior art keywords
- parts
- prebiotic composition
- rice
- sugar
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000209094 Oryza Species 0.000 claims description 46
- 235000007164 Oryza sativa Nutrition 0.000 claims description 46
- 235000009566 rice Nutrition 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 43
- 235000013406 prebiotics Nutrition 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 27
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 26
- 229920000294 Resistant starch Polymers 0.000 claims description 26
- 235000013312 flour Nutrition 0.000 claims description 26
- 235000021254 resistant starch Nutrition 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 22
- 239000006041 probiotic Substances 0.000 claims description 22
- 235000018291 probiotics Nutrition 0.000 claims description 22
- 230000000968 intestinal effect Effects 0.000 claims description 18
- 229920002752 Konjac Polymers 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 235000019698 starch Nutrition 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 15
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 15
- 239000000252 konjac Substances 0.000 claims description 15
- 235000010485 konjac Nutrition 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 14
- 229920002581 Glucomannan Polymers 0.000 claims description 14
- 229940046240 glucomannan Drugs 0.000 claims description 14
- 239000002002 slurry Substances 0.000 claims description 14
- 244000144730 Amygdalus persica Species 0.000 claims description 13
- 229920001202 Inulin Polymers 0.000 claims description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 13
- 235000006468 Thea sinensis Nutrition 0.000 claims description 13
- 229940029339 inulin Drugs 0.000 claims description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 13
- 235000020333 oolong tea Nutrition 0.000 claims description 13
- 239000004386 Erythritol Substances 0.000 claims description 12
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 12
- 229940009714 erythritol Drugs 0.000 claims description 12
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 12
- 235000019414 erythritol Nutrition 0.000 claims description 12
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 11
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 11
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 10
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- 235000020195 rice milk Nutrition 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 229920000856 Amylose Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 30
- 241000186000 Bifidobacterium Species 0.000 description 19
- 241000193468 Clostridium perfringens Species 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000005686 eating Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000009858 acid secretion Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008946 inflammatory intestinal reaction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008104 plant cellulose Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a prebiotic composition and a preparation method and application thereof, wherein the prebiotic composition comprises resistant starch, konjac glucomannan, fructo-oligosaccharide, peach powder, oolong tea powder, erythritol and inulin. By eating the prebiotic composition, the abundance of probiotics in the intestinal tract is improved, the abundance of harmful bacteria is reduced, and the content of short-chain fatty acid in the intestinal tract is improved. By utilizing the synergistic effect of konjac glucomannan and resistant starch, 8-20 times of water by weight is added, and after uniform stirring, stable hydrogel is formed. The probiotic bacteria population changes to achieve the effects of enhancing the human body immunity function, improving the basal metabolism level and promoting digestion and defecation.
Description
Technical Field
The invention relates to the technical field, and particularly relates to a prebiotic composition and a preparation method and application thereof.
Background
In recent years, the research on human probiotics in various countries around the world is more and more intensive, and the structures and the number of different human parasitic strains are found to influence the health condition of a host, namely human beings. Under a healthy physiological state, normal human flora plays an important role in the synthesis of vitamins of a human body, the promotion of growth and development, the metabolism of substances and the immune defense function, is a necessary factor for maintaining the health of the human body, and is a mirror for reflecting the stable environment in a body.
Probiotics and harmful bacteria coexist in the microecosystem of the intestinal tract, and if more probiotics exist, the proportion of the harmful bacteria is less; on the contrary, if the harmful bacteria are more, the proportion of the probiotics is less. Factors influencing the number of human intestinal probiotics are complex, such as age, exercise habits, living habits, diet, and antibiotic usage. In recent years, the importance of probiotics has been increasingly recognized, and the number of intestinal probiotics in vivo has been increased by various methods: the food or the medicine containing the active probiotics is directly taken, and the non-viable bacteria food of the prebiotics is taken to indirectly promote the growth of the probiotics. At present, the sale amount and the use amount of probiotics are far larger than those of prebiotics, but because the disinfection and sterilization requirements are regulated by food laws in China, most foods cannot have the existence of probiotic live bacteria, and the probiotic foods have short retention period and are easy to inactivate.
Prebiotics (prebiotics) are non-digestible food ingredients that act as dietary supplements to beneficially affect the host by selectively stimulating the growth and activity of bacteria in one or a few colonies, thereby improving host health. Most of the prebiotics are not digested and are fermented by the gut flora as they pass through the upper gut. Most importantly, it stimulates the growth of beneficial bacterial flora and not harmful bacteria with potentially pathogenic or putrefactive activity. Therefore, prebiotic effects and use are increasingly appreciated and accepted.
Disclosure of Invention
Aiming at the technical problems in the prior art, the invention provides a prebiotic composition, a preparation method and an application thereof, and the abundance of probiotics in intestinal tracts is improved through the prebiotic composition.
The invention discloses a prebiotic composition, which comprises resistant starch, konjac glucomannan, fructo-oligosaccharide, peach powder, oolong tea powder, erythritol and inulin.
Preferably, the prebiotic composition is prepared from the following raw materials in parts by weight: 55-115 parts of sugar-adapted rice flour, 17-38 parts of konjac glucomannan, 12-30 parts of fructo-oligosaccharide, 13-21 parts of peach powder, 4-16 parts of oolong tea powder, 6-19 parts of erythritol and 15-28 parts of inulin,
wherein the rice flour contains 37-46% of resistant starch.
Preferably, the resistant starch is an amylovorin resistant starch of the type RS 3.
Preferably, the preparation method of the sugar-suitable rice flour comprises the following steps:
crushing sugar-adapted rice and hydrolyzing to obtain rice pulp;
after the rice milk is subjected to acid adjustment, performing pressure maintaining treatment at the temperature of 120 ℃ and 140 ℃, and naturally cooling to obtain starch milk;
and drying and crushing the starch slurry to obtain the powdery sugar-adapting rice flour.
Preferably, the preparation method of the sugar-suitable rice flour comprises the following steps:
cleaning sugar-adapted rice, removing impurities, and pulverizing into 300 mesh raw powder;
adding 2-3 times of water into the raw powder, uniformly mixing, and hydrolyzing for 5-8 hours to obtain rice milk;
adjusting the pH value of the rice slurry to 4-6, performing pressure maintaining treatment at the temperature of 120-140 ℃, and naturally cooling for 4-10 hours to obtain starch slurry;
removing water from the starch slurry in a drying sprayer to obtain powdered sugar-adapting rice flour.
Preferably, in the hydrolysis, ultrasonic waves are applied to enhance the hydrolysis.
Preferably, the saccharified rice is high amylose rice.
The invention also provides a preparation method of the prebiotic composition, which comprises the following steps: taking the raw materials, and mixing uniformly.
The invention also provides application of the prebiotic composition, which is applied to increase the content of probiotics and/or reduce the content of harmful bacteria.
Preferably, the prebiotic composition is used for increasing the content of bifidobacteria and lactobacilli and reducing the content of clostridium perfringens.
Preferably, the prebiotic composition is used to increase the content of intestinal short chain fatty acids, including acetic acid, propionic acid and butyric acid.
Compared with the prior art, the invention has the beneficial effects that: by eating the prebiotic composition, the abundance of probiotics in the intestinal tract is improved, the abundance of harmful bacteria is reduced, and the content of short-chain fatty acid in the intestinal tract is improved.
Drawings
Fig. 1 is a flow chart of a preparation method of the sugar-suitable rice flour of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
The invention is described in further detail below with reference to the attached drawing figures:
a prebiotic composition comprises resistant starch, konjac glucomannan, fructo-oligosaccharide, peach powder, oolong tea powder, erythritol and inulin. By eating the prebiotic composition, the abundance of probiotics in the intestinal tract is improved, the abundance of harmful bacteria is reduced, and the content of short-chain fatty acid in the intestinal tract is improved.
The Resistant Starch (RS) is an insoluble prebiotic, also called Resistant Starch and indigestible Starch, which cannot be enzymatically hydrolyzed in the intestinal tract, but can be fermented with volatile fatty acids in the human gastrointestinal colon. Resistant starches can be classified into four categories, depending on their origin and physicochemical properties: RS1, RS2, RS3 and RS4, and the Rice Resistant Starch (BRS) used in the invention is mainly RS 3.
Konjac Glucomannan (KGM) is a konjac polysaccharide extracted from the tuber of konjac, and its physical structure is similar to a plant cellulose, and is a non-ionic water-soluble polysaccharide. KGM's molecular weight is high, the viscidity is big, can increase the viscosity of food, eat konjaku glucomannan before eating, especially increase satiety after drinking a large amount of water, and the aquogel that forms simultaneously can wrap up food, hinders carbohydrate and grease and absorbs. In the invention, the synergistic action of konjac glucomannan and resistant starch is utilized, 8-20 times of water by weight is added, and after uniform stirring, stable hydrogel is formed and can be prepared by using hot water or cold water.
The fructo-oligosaccharide has the double quality of definite health care function and excellent food ingredients. Has the excellent physiological functions of low heat value, no decayed tooth, promoting the proliferation of bifidobacterium, reducing blood sugar, improving serum lipid, promoting the absorption of trace elements, and the like.
The peach powder is peach extract, and the oolong tea powder is oolong tea extract. The erythritol can increase sweetness, thickness and lubrication of the beverage, reduce bitterness, mask other odors and improve beverage flavor. Inulin is a natural water-soluble dietary fiber which is hardly hydrolyzed and digested by gastric acid; can effectively reduce serum Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase the ratio of high density lipoprotein to low density lipoprotein, improve blood lipid condition, and improve intestinal microbial environment. Inulin is fermented in the intestine to short chain fatty acids and lactate.
The prebiotic composition is prepared from the following raw materials in parts by weight: 55-115 parts of sugar-adapted rice flour, 17-38 parts of konjac glucomannan, 12-30 parts of fructo-oligosaccharide, 13-21 parts of peach powder, 4-16 parts of oolong tea powder, 6-19 parts of erythritol and 15-28 parts of inulin. Wherein the saccharified rice flour contains 37-46% of resistant starch, and the saccharified rice is high amylose rice, and in the specific embodiment, a 'Gong Mi III' rice variety is adopted.
Example 1
The preparation method is characterized by being prepared from the following raw materials in parts by weight: 80 parts of proper sugar rice flour, 20 parts of konjac glucomannan, 12 parts of fructo-oligosaccharide, 18 parts of peach powder, 7 parts of oolong tea powder, 13 parts of erythritol and 16 parts of inulin. Respectively taking the raw materials, and uniformly mixing to obtain a white powder mixture A.
And taking 10g of the mixture A, adding 150g of cold water, and uniformly mixing to obtain the stable white hydrogel.
Example 2
The preparation method is characterized by being prepared from the following raw materials in parts by weight: 70 parts of sugar-adapted rice flour, 30 parts of konjac glucomannan, 22 parts of fructo-oligosaccharide, 16 parts of peach powder, 15 parts of oolong tea powder, 6 parts of erythritol and 22 parts of inulin. Respectively taking the raw materials, and uniformly mixing to obtain a white powder mixture B.
And (3) adding 200g of cold water into 10g of the mixture B, and uniformly mixing to obtain the stable white hydrogel.
Example 3
The preparation method is characterized by being prepared from the following raw materials in parts by weight: 55 parts of proper sugar rice flour, 38 parts of konjac glucomannan, 15 parts of fructo-oligosaccharide, 20 parts of peach powder, 5 parts of oolong tea powder, 7 parts of erythritol and 17 parts of inulin. Respectively taking the raw materials, and uniformly mixing to obtain a white powder mixture C.
And adding 250g of warm water into 10g of the mixture C, and uniformly mixing to obtain the stable white hydrogel.
Example 4
The preparation method is characterized by being prepared from the following raw materials in parts by weight: 110 parts of proper sugar rice flour, 32 parts of konjac glucomannan, 30 parts of fructo-oligosaccharide, 14 parts of peach powder, 8 parts of oolong tea powder, 19 parts of erythritol and 20 parts of inulin. Respectively taking the raw materials, and uniformly mixing to obtain a white powder mixture B.
Take 10g of mixture B, add 220g of hot water (80-100 degrees) slowly while stirring and mixing to obtain a stable white hydrogel.
Example 5
The preparation method is characterized by being prepared from the following raw materials in parts by weight: 60 parts of proper sugar rice flour, 17 parts of konjac glucomannan, 20 parts of fructo-oligosaccharide, 13 parts of peach powder, 12 parts of oolong tea powder, 17 parts of erythritol and 28 parts of inulin. Respectively taking the raw materials, and uniformly mixing to obtain a white powder mixture B.
And adding 80g of warm water into 10g of the mixture B, and uniformly mixing to obtain the stable white hydrogel.
The preparation method of the sugar-suitable rice flour comprises the following steps:
step 101: pulverizing sugar-adapted rice, and hydrolyzing to obtain rice slurry. Ultrasonic waves can be applied during hydrolysis to enhance hydrolysis, increase hydrolysis efficiency, and increase the resistant starch content in the final product
Step 102: after the rice milk is subjected to acid adjustment, after the rice milk is subjected to pressure maintaining treatment at the temperature of 120 ℃ and 140 ℃, the rice milk is naturally cooled to obtain starch milk. In a slightly acidic environment, the starch is moderately hydrolyzed, so that the generation efficiency of later resistant starch can be increased, and the pH value can be adjusted to 4, 5 and 6 levels.
Step 103: and drying and crushing the starch slurry to obtain the powdery sugar-adapting rice flour.
In the specific embodiment, the following preparation method of the sugar-suitable rice flour is adopted:
step 201: cleaning sugar-adapted rice, removing impurities, and pulverizing into 300 mesh raw powder.
Step 202: adding 2-3 times of water into the raw powder, uniformly mixing, and hydrolyzing for 5-8 hours to obtain rice milk. In the hydrolysis, ultrasonic waves may be introduced to enhance the hydrolysis.
Step 203: adjusting the pH value of the rice slurry to 4-6, performing pressure maintaining treatment at the temperature of 120-140 ℃, and naturally cooling for 4-10 hours to obtain starch slurry. The cover of the pressurizer can be opened to cool naturally when the pressure drops to a normal value. It should be noted that the aqueous solution cannot reach more than 100 ℃ under normal pressure, and needs to be kept under a certain pressure, and the pressure in the pressure-maintaining device can be determined by the temperature.
Step 204: removing water from the starch slurry in a drying sprayer to obtain powdered sugar-adapting rice flour. However, the method is not limited to this, and other drying methods may be used, and the dried solid may be pulverized into powder. Or centrifuging the starch slurry, removing water soluble substance, drying and pulverizing the precipitate to obtain the rice flour.
The water content of the rice flour is 10-15%, and the content of RS3 resistant starch is 37-46%. The application adopts the Goni method to detect the content of resistant starch: when the content of the resistant starch is determined, the soluble starch is removed, then the resistant starch is hydrolyzed, then the content of reducing sugar in the resistant starch is determined, and finally the content is converted into the content of the resistant starch.
In a specific test, mixture B of example 2 was selected for further testing.
First, mouse test
18-22g of experimental animal research institute (license number: SCXK- (Jing) 2004-0001) bred and 40 healthy and clean male mice are selected and divided into four groups: control, low, medium and high dose groups, 10 of them.
Wherein the low dose group, the medium dose group and the high dose group were orally gavaged twice daily to mice with the corresponding dose of the test substance (mixture B) dissolved in water 8 times the weight of the test substance, and the gavage volume was 0.10mL/10g of the weight of the mice; and meanwhile, the control group is perfused with water with the same volume. Each group of mice was fed at normal consumption. And continuously gavage for 30 days to detect the body weight, intestinal short-chain fatty acid (SCFA) and intestinal flora of the mice.
1. The results of the measurement of the body weight of the mice are shown in the following table:
as can be seen from the table, the test substances had no adverse effect on the growth of the mice, and the weight of the mice in all groups was increased, but the weight of the mice in the high-dose group rose slowly.
2. Short Chain Fatty Acids (SCFA), also known as volatile fatty acids, refer to organic fatty acids with 1-6 carbon atoms, which are produced mainly by the fermentation of undigested carbohydrates by anaerobic bacteria in the colonic cavity, including acetic acid, propionic acid, butyric acid, valeric acid, isovaleric acid, isobutyric acid, etc. The short chain fatty acid has the functions of maintaining the electrolyte balance in intestinal tract, inducing cancer cell differentiation and apoptosis, regulating gene expression, etc. Acetic acid, propionic acid and butyric acid are main short chain fatty acids in the intestinal tract and play an important role in regulating and controlling the absorption of nutrient substances in the intestinal tract, the production of hormones and the energy metabolism. The invention adopts a gas chromatography-mass spectrometry (GC-MS) method for detection, and the detection results are shown in the following table:
wherein, the secretion of acetic acid in the high-dose group is increased by 10.50 percent, and the difference is significant (p is less than 0.05); the acetic acid of the low-dose group is increased by 14.87 percent, the difference is very significant (p is less than 0.01), the acetic acid content of each group is improved, and the prebiotics have a promoting effect on the acetic acid secretion.
The secretion of small propionic acid in the low-dose group and the high-dose group is increased by 28.57% and 11.56%, respectively, and the difference is significant (p < 0.05); the secretion of propionic acid in the cecal contents of the mice in the medium-dose group is increased, and has a significant difference (p is less than 0.05) compared with a control group, and the secretion is increased by 3.40 percent respectively, so that the propionic acid content of each group is improved, and the prebiotics have a promoting effect on propionic acid secretion.
The butyric acid production of each group was increased to different extents, and the high dose group had the highest butyric acid secretion, followed by the medium dose group and the low dose group. The secretion of butyric acid in the caecum content of the mice in the high-dose group and the middle-dose group is respectively increased by 92.75 percent and 78.98 percent, and has very significant difference compared with the control group (p is less than 0.01); the secretion of butyric acid was also increased by 22.46% in the low dose group compared to the control group, with a significant difference compared to the control group (p < 0.05). Therefore, the content of butyric acid in each group is improved, and the prebiotics of the invention have a promoting effect on the secretion of butyric acid. Butyric acid is the primary raw material for normal colon cell growth, and can stimulate the repair of intestinal villi, stimulate the absorption of sodium by colon to meet the requirement of human body for water storage, reduce the absorption of fat cells, and inhibit the synthesis of cholesterol; in addition, butyric acid can also inhibit intestinal inflammatory reaction and inhibit tumor cell proliferation; butyric acid also promotes the secretion of pancreatic islets and lowers blood sugar.
The total production of SCFAs (acetic, propionic, isobutyric and butyric) varied to varying degrees, with the highest increase in the high and medium dose groups being 30.78% (p <0.01) and 28.53% (p <0.01), respectively, and the results of the test showed that the intake of different doses of prebiotic compositions had a dose-effect relationship to the metabolic level of total SCFAs in the gut. SCFAs reduce the risk of gastrointestinal disorders, cancer and cardiovascular disease. Acetic acid is the major SCFAs in the large intestine and enhances cholesterol synthesis after absorption.
3. In the invention, the bifidobacteria and the clostridium perfringens in the intestinal flora are detected.
The operation method comprises the following steps: before a sample is tested, counting mouse excrement in an aseptic manner, placing the mouse excrement in an aseptic container, weighing the mouse excrement by using an analytical balance, and recording the weight; then, in a clean bench, sterile operation, add diluent, dilute to 1: 102Fully oscillating and mixing uniformly, and sequentially diluting by 10 times to 1: 108For each test strain, the appropriate dilution was selected and the corresponding test plate was inoculated as pre-test data.
24h after the last test administration, samples were again taken and diluted as described above, each species was assayed, the appropriate dilution was selected, and the corresponding assay plate was inoculated as post-test data.
The detection method of the bifidobacterium and the clostridium perfringens is shown in the following table:
according to the judgment standard of 'technical Specification for testing and evaluating health food' (2003 edition). Comparing the change conditions of the bifidobacteria and the clostridium perfringens before and after the experiment and between groups, wherein the comparison difference between the experimental group and the experimental group before and after the experiment is significant, or the comparison difference between the experimental group and the control group after the experiment is significant, and the comparison difference between the experimental group and the experimental group before and after the experiment is significant, and when the bifidobacteria is obviously increased or the clostridium perfringens is reduced, the animal test result of the tested sample can be judged to be positive.
The results of the bifidobacterium flora detection are shown in the following table:
after the test object is given, the number of the bifidobacteria in the medium-dose group and the high-dose group is increased and has a significant difference (P <0.05) compared with the control group, and the bifidobacteria flora in the high-dose group is obviously higher than that in the medium-dose group, so that an increase relationship is presented. Wherein the Bifidobacterium is used as intestinal probiotic.
The results of the clostridium perfringens flora detection are shown in the following table:
as can be seen from the above table, the low dose group showed no significant difference (P >0.4) when compared with the control group before and after the test substance administration, the intermediate dose group showed significant difference (P >0.05) in the number of Clostridium perfringens in the high dose group, and the number of Clostridium perfringens in the intestinal tract was significantly reduced. Clostridium perfringens acts as a harmful bacterium.
Therefore, after the test object is given, the weight increase of the mouse can be controlled without influencing the growth and development of the mouse; short chain fatty acids in the mouse intestinal tract are increased; the change of the intestinal flora of the mouse is obvious, wherein the detection of the probiotic bifidobacterium flora is obviously increased and is positively correlated with the feeding dosage; the harmful bacteria represented by clostridium perfringens are also related to feeding of composite prebiotics with different dosages, and the clostridium perfringens is obviously reduced after feeding. Namely, the abundance of the intestinal flora of the mice can be changed by feeding different dosages of the prebiotic composition, namely, the beneficial bacteria are increased, and the harmful bacteria are reduced.
Second, food testing
40 adult volunteers were selected as experimental population, with 7 male and 13 female patients who did not suffer from gastrointestinal disease within one month and did not take antibiotics within one month, and the age was between 26-54 years. Taking the mixture B as a test object, subpackaging according to 8 g/bag, taking 16g/60KG as a reference eating amount, taking 2 times a day for each person, preparing with water according to a ratio of 1:8 during eating, and adding cold water and hot water, wherein the original eating habits of experimental people are not changed.
The experimental population was randomly divided into 2 groups, one group was the test group, and the test subjects were fed in the above manner, and the other group was the control group, and the test group was drunk with the same volume of plain boiled water. Before test, aseptically acquiring feces of a subject for culture, detecting intestinal flora, and simultaneously detecting blood pressure and heart rate; after 30 days of testing, feces of the subject were aseptically harvested for culture, and intestinal flora was examined, as well as blood pressure and heart rate. The three intestinal bacterial species tested were: bifidobacteria, lactobacilli and clostridium perfringens.
According to the judgment standard of 'technical Specification for testing and evaluating health food' (2003 edition). Comparing the change conditions of the bifidobacteria, the lactobacilli and the clostridium perfringens of the feeding group and the control group before and after the experiment, wherein the comparison difference between the experimental group and the control group before and after the experiment is significant, or the comparison difference between the experimental group and the control group after the experiment is significant, and the comparison difference between the experimental group and the control group before and after the experiment is significant, the test sample can be judged to be positive according to the following one: (1) the bifidobacteria and/or the lactobacilli in the excrement are obviously increased, the clostridium perfringens is reduced or not increased, and the enterobacteria, the enterococci and the bacteroides are not obviously changed; (2) the stool has significantly increased bifidobacteria and/or lactobacilli, decreased or no clostridium perfringens, and significantly increased enterobacteria and/or enterococci and bacteroides, but at a lower level than the bifidobacteria/lactobacilli.
The results are shown in the following table:
as can be seen from the above table, the tested group and the control group have significant difference (p <0.01), and compared with the control group, the tested group has significantly increased bifidobacterium by 21.4%, increased lactobacillus by 16.2%, and significantly decreased clostridium perfringens by 11.9%, that is, all three indexes are positive. Through comparison experiments of 20 persons and 30 days, probiotics represented by bifidobacteria and lactobacilli are obviously increased, and harmful bacteria represented by clostridium perfringens are obviously reduced, so that the prebiotic composition can improve the abundance of human intestinal flora and promote the intestinal health.
Therefore, the prebiotic composition of the invention changes the abundance of human intestinal flora by selectively stimulating the growth and activity of bacteria in one or more bacterial colonies, thereby producing beneficial effects on the host; particularly, the number of bifidobacteria and lactic acid bacteria can be obviously increased, and the clostridium perfringens can be reduced. The functions of activating the proliferation of probiotics and inhibiting harmful bacteria are realized, thereby regulating the abundance of intestinal flora of human body. The probiotic bacteria population changes to achieve the effects of enhancing the human body immunity function, improving the basal metabolism level and promoting digestion and defecation. These effects are not a direct effect of complex prebiotics, but rather a function of prebiotics that alter the composition of the gastrointestinal flora and the abundance of beneficial bacteria.
In order to detect the safety of eating the prebiotic composition, the heart rate detection of blood pressure and human experience indexes such as spirit, sleep, diet, defecation and the like are added. Before and after the test, the blood pressure and the heart rate of the test group and the control group are basically normal and have no obvious change; normal spirit, sleep, diet, and stool and urine; blood, urine and frequent stool size examination is basically normal and has no obvious change; the viewing and viewing rates of the abdomen B-ultrasound, electrocardiogram and X-ray chest are basically normal.
The data of the human body feeling indexes are collected by adopting a questionnaire type, parts without obvious body feeling are eliminated, and the collected data are shown in the following table:
as can be seen from the above table, the tested subjects can improve the phenomena of tiredness and inappetence, and also can effectively promote defecation, but the phenomenon of abdominal distension is also caused, and the phenomenon that the exhaust is increased in a special part of the tested persons is more obvious. After the test substance is taken, the defecation status of part of the test subjects is improved, and other adverse reactions are avoided. The results show that the two groups are comparable, the tested samples have no adverse effect on the subjects, and allergy and other adverse reactions are not observed.
The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and various modifications and changes will occur to those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A prebiotic composition comprising resistant starch, konjac glucomannan, fructo-oligosaccharides, peach powder, oolong tea powder, erythritol, and inulin.
2. The prebiotic composition of claim 1, which is prepared from the following raw materials in parts by weight: 55-115 parts of sugar-adapted rice flour, 17-38 parts of konjac glucomannan, 12-30 parts of fructo-oligosaccharide, 13-21 parts of peach powder, 4-16 parts of oolong tea powder, 6-19 parts of erythritol and 15-28 parts of inulin, wherein the sugar-adapted rice flour contains 37-46% of resistant starch.
3. Prebiotic composition according to claim 2, characterised in that the resistant starch is an amylovorin resistant starch of the type RS 3.
4. The prebiotic composition of claim 2, wherein the process of making the sugar-suitable rice flour comprises:
crushing sugar-adapted rice and hydrolyzing to obtain rice pulp;
after the rice milk is subjected to acid adjustment, after pressure maintaining treatment at the temperature of 120 ℃ and 140 ℃, natural cooling is carried out to obtain starch milk;
and drying and crushing the starch slurry to obtain the powdery sugar-adapting rice flour.
5. The prebiotic composition of claim 4, wherein the process of making the sugar-suitable rice flour comprises:
cleaning sugar-adapted rice, removing impurities, and pulverizing into 300 mesh raw powder;
adding 2-3 times of water into the raw powder, uniformly mixing, and hydrolyzing for 5-8 hours to obtain rice milk;
adjusting the pH value of the rice slurry to 4-6, performing pressure maintaining treatment at the temperature of 120-140 ℃, and naturally cooling for 4-10 hours to obtain starch slurry;
removing water from the starch slurry in a drying sprayer to obtain powdered sugar-adapting rice flour.
6. Prebiotic composition according to claim 5, characterised in that in the hydrolysis ultrasound is introduced to enhance the hydrolysis.
7. Prebiotic composition according to claim 2, characterised in that the saccharidic rice is high amylose rice.
8. A process for the preparation of a prebiotic composition according to any one of claims 1 to 7 comprising: taking the raw materials, and mixing uniformly.
9. Use of a prebiotic composition according to any of claims 1 to 7 for increasing the level of probiotic bacteria and/or for decreasing the level of harmful bacteria.
10. The use according to claim 9, wherein the prebiotic composition is used to increase the content of intestinal short chain fatty acids, including acetic acid, propionic acid and butyric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110313079.3A CN112931883A (en) | 2021-03-24 | 2021-03-24 | Prebiotic composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110313079.3A CN112931883A (en) | 2021-03-24 | 2021-03-24 | Prebiotic composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112931883A true CN112931883A (en) | 2021-06-11 |
Family
ID=76228425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110313079.3A Pending CN112931883A (en) | 2021-03-24 | 2021-03-24 | Prebiotic composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112931883A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112890177A (en) * | 2021-02-24 | 2021-06-04 | 云南屯屯麦生物技术研究有限公司 | Composition for reducing postprandial blood glucose level during pregnancy and preparation method thereof |
| CN113854569A (en) * | 2021-08-25 | 2021-12-31 | 河北天烨食品科技有限公司 | Probiotic nutrient, preparation method thereof and method for improving survival rate of edible probiotics |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
| CN106261498A (en) * | 2016-08-09 | 2017-01-04 | 云南屯屯麦生物技术研究有限公司 | A kind of powder with medical function food and application thereof |
| CN106551402A (en) * | 2015-09-25 | 2017-04-05 | 天津国际生物医药联合研究院 | Super prebioticses and preparation method thereof |
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | A laxative compound prebiotic and its preparation method and application |
| CN108402371A (en) * | 2018-01-19 | 2018-08-17 | 广东润源中天生物科技有限公司 | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes |
| CN110710690A (en) * | 2018-07-12 | 2020-01-21 | 上海来益生物药物研究开发中心有限责任公司 | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria |
| CN112385850A (en) * | 2020-11-13 | 2021-02-23 | 山东第一医科大学附属内分泌与代谢病医院 | Meal replacement powder with effects of reducing blood fat and weight and improving intestinal flora |
-
2021
- 2021-03-24 CN CN202110313079.3A patent/CN112931883A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
| CN106551402A (en) * | 2015-09-25 | 2017-04-05 | 天津国际生物医药联合研究院 | Super prebioticses and preparation method thereof |
| CN106261498A (en) * | 2016-08-09 | 2017-01-04 | 云南屯屯麦生物技术研究有限公司 | A kind of powder with medical function food and application thereof |
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | A laxative compound prebiotic and its preparation method and application |
| CN108402371A (en) * | 2018-01-19 | 2018-08-17 | 广东润源中天生物科技有限公司 | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes |
| CN110710690A (en) * | 2018-07-12 | 2020-01-21 | 上海来益生物药物研究开发中心有限责任公司 | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria |
| CN112385850A (en) * | 2020-11-13 | 2021-02-23 | 山东第一医科大学附属内分泌与代谢病医院 | Meal replacement powder with effects of reducing blood fat and weight and improving intestinal flora |
Non-Patent Citations (3)
| Title |
|---|
| VIPUL DAVE ET AL.: "Liquid crystalline, rheological and thermal properties of konjac glucomannan", 《POLYMER》 * |
| 云南省农业科学院生物技术与种子资源研究所: "云功牌适糖米 国际领先的高科技功能稻米", 《云南科技管理》 * |
| 黄继红: "《抗性淀粉生产技术及其应用》", 31 January 2017, 河南科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112890177A (en) * | 2021-02-24 | 2021-06-04 | 云南屯屯麦生物技术研究有限公司 | Composition for reducing postprandial blood glucose level during pregnancy and preparation method thereof |
| CN113854569A (en) * | 2021-08-25 | 2021-12-31 | 河北天烨食品科技有限公司 | Probiotic nutrient, preparation method thereof and method for improving survival rate of edible probiotics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roberfroid | Prebiotics and probiotics: are they functional foods? | |
| Tester et al. | Glucomannans and nutrition | |
| CN102657262B (en) | Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants | |
| CN104642870B (en) | A kind of prebiotic compositions | |
| Thammarutwasik et al. | Prebiotics-A Review. | |
| US10959452B2 (en) | Composition for induced bowel movement and diet and preparation method thereof | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN103211230A (en) | Dietary fiber formulation and method of administration | |
| CN113519631B (en) | Low-blood-sugar-load middle-aged and elderly-people modified milk powder for assisting in reducing blood sugar and preparation method thereof | |
| CN108477617A (en) | A kind of probiotic powder and preparation method thereof to relax bowel | |
| WO2007114378A1 (en) | Composition for beverage or food | |
| TWI744028B (en) | Prebiotic composition for promoting growth of clostridium butyricum and uses thereof | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN105982009A (en) | Composition for regulating human body intestinal micro-ecology | |
| CN111406800A (en) | Low-GI yogurt suitable for diabetics and preparation method thereof | |
| Gupta et al. | Xylooligosaccharide-a valuable material from waste to taste: a review | |
| Angus et al. | Prebiotic ingredients with emphasis on galacto‐oligosaccharides and fructo‐oligosaccharides | |
| CN109329688A (en) | Sugar friendly probiotic solid drink | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| CN107751703A (en) | A kind of solid beverage and its detection method with regulation gut flora function | |
| CN109717377A (en) | The processing method of vegetarian diet meal replacement powder with lower blood-fat and reduce weight function | |
| CN107950864A (en) | A kind of symphysis unit paddy vegetable meal replacement powder and its preparation method and application | |
| TW202202160A (en) | Composition for facilitating defecation and uses thereof | |
| WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
| JP6042537B2 (en) | Fat binder obtained from brewing process biomass |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210611 |
|
| RJ01 | Rejection of invention patent application after publication |